Aier Eye's Hong Kong H-Share Bid Nears Six Months on File as A+H Queue Grows
The eye hospital group filed for an A+H listing in May and is still on its first draft. A new HKEX waiver means the six-month mark need not force a refiling.

What to know
- Aier Eye Hospital Group's Hong Kong application proof is dated May 27, 2026, and the HKEXnews active list still showed only that first submission as of Nov. 13.
- Under a temporary HKEX waiver announced Aug. 21, eligible new listing applications stay valid for 12 months instead of six, if conditions are met.
- The draft names Huatai Financial Holdings (Hong Kong) as sole sponsor and shows 2025 revenue of 22.35 billion yuan, with 842 eye centers including 179 overseas.
- Several other large mainland companies, including Zhejiang Chint Electrics, Shenzhen Capchem Technology, Yonyou Network Technology and Ningbo Deye Technology, also have Hong Kong applications on file from July and August.
HONG KONG
Aier Eye Hospital Group, the Shenzhen-listed chain that describes itself in its filing as the world's largest ophthalmic medical services group, has been in Hong Kong's listing queue for almost six months. Its draft prospectus, known as an application proof, is dated May 27, and the exchange's list of active applications still showed only that first submission as of Friday, Nov. 13.
Nothing in the public record says the plan has stalled, and the six-month mark on Nov. 27 carries less weight than it once did. Hong Kong listing applications have traditionally been valid for six months, after which a company had to refile. On Aug. 21, the exchange announced a temporary waiver, running until Aug. 20, 2029, that extends the validity of eligible new listing applications to 12 months from the date of the application form, The Standard and the exchange's announcement both reported. Applications already valid on that date can qualify, provided the exchange has not suspended vetting, regulators have not issued a major concerns letter and the sponsor does not change. Investors watching the A+H pipeline, in which companies already traded in Shanghai or Shenzhen add a second line of shares in Hong Kong, will be looking for an updated filing or a hearing as the next sign of progress.
What the draft shows
The application proof gives English-language readers a detailed look at the business. The company said it operated 842 ophthalmic medical centers at the end of 2025: 663 in mainland China and 179 overseas, spread across Hong Kong, Europe, the United States and Southeast Asia. It recorded 18.89 million outpatient visits and 1.68 million surgical procedures last year, and lists Huatai Financial Holdings (Hong Kong) as its sole sponsor.
Revenue rose to 22.35 billion yuan in 2025 from 20.98 billion yuan in 2024 and 20.37 billion yuan in 2023, according to the filing. Profit for the year moved the other way, slipping to 3.47 billion yuan from 3.74 billion yuan, and the margin narrowed to 15.5% from 17.7%. Refractive services, mainly vision-correction surgery, remained the biggest line at 8.38 billion yuan, or 37.5% of revenue. Operating cash flow was 5.97 billion yuan.
The founder, Chen Bang, and the holding company Aier Investment together held about 49.82% of the shares and controlled about 49.99% of the votes at the latest practicable date, the draft said. The size of the offering, the price range and the use of proceeds are all redacted, as is standard at this stage.
Why Hong Kong, and why now
Aier's board voted on April 23 to pursue a main board listing in Hong Kong, Bamboo Works reported, about a month after overseas media first reported a possible secondary float. The shift was notable because at a shareholder meeting last year Chen had said the company had no plans for H shares, citing its solid financing capacity and a lack of suitable overseas acquisition targets, according to the same report.
The company told investors it wanted broader access to international capital to support its expansion abroad. That business is growing faster than the domestic one. Overseas revenue rose 16.47% to 3.06 billion yuan in 2025, lifting its share of sales to 13.68% from 12.51%, Bamboo Works reported, while the domestic gross margin fell 1.22 percentage points to 47.26%. The application proof highlights Clínica Baviera, which Aier bought in 2017 and which it says has kept the number one market share in Spain since then.
Bamboo Works also noted that Aier's shares had fallen about 70% from their July 2021 peak of 42.49 yuan, when the company's market value approached 400 billion yuan, and argued that the listing looked more like an effort to reshape market perceptions than a response to funding needs. The outlet put Aier's valuation at about 30 times earnings, against about 15 times for Hong Kong-listed C-MER Medical. First-quarter 2026 revenue rose 6.15% to nearly 6.40 billion yuan and net profit climbed 12.46% to 1.18 billion yuan, it reported.
A crowded A+H queue
Aier is far from alone. HKEXnews shows application proofs on file from several other large mainland groups, including Zhejiang China Commodities City Group (dated May 29), Yonyou Network Technology (July 15), Ningbo Deye Technology (July 28), and Zhejiang Chint Electrics and Shenzhen Capchem Technology (both Aug. 28). All of them were still on their first application proof as of Nov. 13, according to the exchange's list.
The draw is plain. Zhongji Innolight's US$7.8 billion Hong Kong listing in July was part of a year in which total Hong Kong IPO proceeds passed US$51.6 billion, The Standard reported on Nov. 4, citing Bloomberg. Shanghai-listed Semight Instruments has also hired banks for a planned 2027 Hong Kong listing that could raise more than US$1 billion, according to that report. For background on the year so far, see our earlier report on Hong Kong's IPO fundraising pace and our look at Hong Kong IPOs trading below their offer prices.
New filings have thinned, though. Only three applications on the exchange's active list carried November dates through Friday. For Aier, the next document on HKEXnews will say a good deal: a post-hearing information pack, which appears once the listing committee has reviewed a deal, would put a launch within reach, while a revised application proof with updated financials would signal a longer timetable.
Sources
- HKEXnews (Hong Kong Exchanges and Clearing): Application Proof of Aier Eye Hospital Group Co., Ltd. (May 27, 2026)
- Bamboo Works: Looking for overseas growth, Aier Eye seeks Hong Kong listing
- HKEXnews (Hong Kong Exchanges and Clearing): Application Proofs and Post Hearing Information Packs: Main Board active applications (Nov. 13, 2026)
- HKEXnews (Hong Kong Exchanges and Clearing): Application Proof of Zhejiang Chint Electrics Co., Ltd. (Aug. 28, 2026)
- The Standard: HKEX extends validity period of new listing applications from six to 12 months (Aug. 21, 2026)
- Mondo Visione (HKEX announcement): HKEX: The Exchange To Extend Validity Period Of New Listing Applications (Aug. 21, 2026)
- The Standard: Semight Instruments to raise over US$1 billion in 2027 HK listing, Bloomberg reports (Nov. 4, 2026)
Our standards: Capital Times reports under the principles set out in our Editorial Standards and Ethics Policy. Spotted an error? Report it to our editors.







